tbuckley/cabot-search huggingface dataset:
OP0303-PARE Raising Public Awareness on Osteoarthritis through An Educational Campain
Authors: N. Avielle, K. Blidberg, B. Svanberg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Swedish Rheumatism Association has in collaboration with Netdoktor.se, Sweden9s leading public portal for health issues, developed an online test with the aim of improving public awareness of osteoarthritis. There are many myths surrounding osteoarthritis that we need to address, for example that osteoarthritis is just something one needs to accept rather than it being treatable. <h3>Objectives</h3> There is a lack of knowledge in the Swedish society about osteoarthritis. With this online test we want to improve the understanding of the condition. Without basic knowledge it is hard for a patient to demand one9s right in the health care system. <h3>Methods</h3> The Swedish Rheumatism Association has in collaboration with Netdoktor.se put together a team of experts to review all information in the test. The experts have different backgrounds from both the medicine, IT and PR. <h3>Results</h3> This far the test has been very successful, a total of 9 720 individuals have completed the whole test and 35 388 have visited the website for more information. The test shows that among women with symptoms of osteoarthritis, who had sought medical advice, only 40% have received any explanation on what may cause their joint pain. And out of these women, 23% use naturopathic drugs for their condition. The numbers are almost the same for men; only 41% have received an explanation on what may cause their joint pain and 20% uses naturopathic drugs. Out of the category which already has been diagnosed with osteoarthritis, 62% have not been invited to join an evidence based supportive osteoarthritis self-management program lead by a physiotherapists. The program helps the patient to gain knowledge to improve their health condition, a program which the Swedish Rheumatism Association recommends. <h3>Conclusions</h3> The Swedish Rheumatism Association is able to use the different statistic that the test generates to raise awareness about osteoarthritis. Approximately 800 000 Swedes suffer from osteoarthritis in one or more joints. It is in other words a huge public health issue and more needs to be done for a better care of this patient group. Our aim is that the health care system will increasingly recommend their patients to the supportive osteoarthritis self-management program. <h3>Disclosure of Interest</h3> None declared
PTU-021 Efficacy, Safety and Complications of Endoscopic Submucosal Dissection for Colonic Lesions in the Very Elderly Patients above Eighty Years of Age
Authors: J Woo, J Matsuoka, Y Kowazaki, M Nishimura
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic submucosal dissection (ESD) has been safely utilised for resection of colonic lesions.<sup>1,2</sup> More evidence is required in determining the safety profile of ESD in colonic lesion resection, particularly in the super elderly patients ≥80 years of age. In Japan, ESD is approved for both large adenomatous and superficial neoplastic lesions. Our hospital has been a centre for elderly gastroenterology care in North Western Tokyo, and has been an established ESD centre since 2013. The aim of this study is to provide further comparative data on the safety and feasibility of ESD provision in elderly patients ≥80 years of age. <h3>Methods</h3> A single centre retrospective analysis of our hospital’s ESD database was undertaken. Patients had ESD performed for colonic lesions from July 2013 till December 2015 were included and divided into 2 groups-either ≥80 years old or &lt;80 years old. Data on baseline characteristics (age, sex, comorbidity), ESD procedure data, complications and specimen histology were analysed and compared. <h3>Results</h3> A total of 119 patients were included in this study of which 41 (34%) were ≥80 years of age and 78 (66%) were &lt;80 years old. Baseline comorbidity were indifferent between the two groups (p = 0.49). All complications recorded including bleeding, hypo/hypertension, desaturation and tachy/bradyarrythmia were all successfully corrected during the ESD procedure. Bleeding episodes were treated with needle knife coagulation and/or coagrasper. Post ESD, 2.5% of ≥80 group and 4% of the &lt; 80 age group experienced bleeding requiring urgent endoscopy. All cases of post ESD bleeding occurred within 24 hours post ESD, and were all successfully treated endoscopically without subsequent rebleed. There was no peforation, followup surgery or intensive-care admission reported. Overall, no major adverse events reported during or post ESD. A colonic ESD video is included for demonstration. <h3>Conclusion</h3> ESD is a safe and minimally invasive procedure for resection of colonic lesions even in elderly patients above 80 years of age. In addition to an excellent en-bloc resection rate, direct visualisation of the submucosal layer during the dissection process in experienced operators allows a safer and virtually perforation free resection. <h3>References</h3> 1 Tamegai Y, Saito Y, <i>et al</i>. Endoscopic submucosal dissection: a safe technique for colorectal tumours. <i>Endoscopy</i>. 2007;<b>39</b>(5):418–422. 2 Saito Y, Uraoka, <i>et al</i>. Endoscopic treatment of large superficial colorectal tumours: a case series of 200 endoscopic submucosal dissections. <i>GI Endoscopy</i> 2007;<b>66</b>(5):966–73. <h3>Disclosure of Interest</h3> None Declared
Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study
Authors: Fabio Efficace, Gianluca Gaidano, Massimo Breccia, Pasquale Niscola, Francesco Cottone, Luana Fianchi, Maria Teresa Voso, Giovanni Caocci, Francesco Buccisano, Emanuele Angelucci, Valeria Santini, Reinhard Stauder, Uwe Platzbecker, Alessandra Ricco, Nicola Di Renzo, David Bowen, Franco Mandelli
Journal: Blood (2015)
MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy
Authors: Zhao Cui, Li-jun Xie, Fang-jin Chen, Zhi-yong Pei, Li-jie Zhang, Zhen Qu, Jing Huang, Qiu-hua Gu, Yi-miao Zhang, Xin Wang, Fang Wang, Li-qiang Meng, Gang Liu, Xu-jie Zhou, Li Zhu, Ji-cheng Lv, Fan Liu, Hong Zhang, Yun-hua Liao, Lu-hua Lai, Pierre Ronco, Ming-hui Zhao
Journal: Journal of the American Society of Nephrology (2016)

Epitopes of phospholipase A2 receptor (PLA2R), the target antigen in idiopathic membranous nephropathy (iMN), must be presented by the HLA–encoded MHC class II molecules to stimulate autoantibody production. A genome–wide association study identified risk alleles at HLA and PLA2R loci, with the top variant rs2187668 within HLA-DQA1 showing a risk effect greater than that of the top variant rs4664308 within PLA2R1. How the HLA risk alleles affect epitope presentation by MHC class II molecules in iMN is unknown. Here, we genotyped 261 patients with iMN and 599 healthy controls at the HLA-DRB1, HLA-DQA1, HLA-DQB1, and HLA-DPB1 loci with four-digit resolution and extracted the encoded amino acid sequences from the IMGT/HLA database. We predicted T cell epitopes of PLA2R and constructed MHC-DR molecule-PLA2R peptide-T cell receptor structures using Modeler. We identified DRB1*1501 (odds ratio, 4.65; 95% confidence interval [95% CI], 3.39 to 6.41; P &lt;0.001) and DRB1*0301 (odds ratio, 3.96; 95% CI, 2.61 to 6.05; P &lt;0.001) as independent risk alleles for iMN and associated with circulating anti–PLA2R antibodies. Strong gene-gene interaction was noted between rs4664308(AA) and HLA-DRB1*1501/DRB1*0301. Amino acid positions 13 ( P &lt;0.001) and 71 ( P &lt;0.001) in the MHC-DR β 1 chain independently associated with iMN. Structural models showed that arginine13 and alanine71, encoded by DRB1*1501, and lysine71, encoded by DRB1*0301, facilitate interactions with T cell epitopes of PLA2R. In conclusion, we identified two risk alleles of HLA class II genes and three amino acid residues on positions 13 and 71 of the MHC-DR β 1 chain that may confer susceptibility to iMN by presenting T cell epitopes on PLA2R.
AB0750 Analgetic Effect of Nsaids in Chronic Knee Osteoarthritis with A “Clinical” Central Sensitization
Authors: E. Turovskaia, L. Alekseeva, E. Filatova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> NSAIDs are widely used for therapy nociceptive pain in osteoarthritis (OA) patients. But in 27% - 61% case this treatment fails to reduce mean pain levels beyond minimal clinically important thresholds [1]. Recent studies have demonstrated that chronic knee OA mechanisms besides nociceptive pain also include central sensitization (CS) (neuroplastic changes in the posterior horn) [2]. CS characterized with neuropathic (NP) phenomena spontaneous and evoked (34% cases), referred hyperalgesia and neurophysiological changes (low pressure pain threshold). <h3>Objectives</h3> to evaluate the efficacy of NSAID in patients with "clinical" CS. <h3>Methods</h3> 40 women (age 55±75), II-III grade by Kellgren-Lawrence with chronic knee OA were included. Patients were divided in groups in accordance with the results of neuropathic test DN4 (screening test for CS): patients with positive DN4 (n=11) and patients with negative DN4 (n=29) and accordance with presence of spontaneous NP phenomena (for ex. burning, tingling, current rush): patients with spontaneous NP phenomena (n=29) and patients without spontaneous NP phenomena. Dynamic of OA severity by WOMAC (mm) and pain intensity by VAS (mm) were assessed between groups. <h3>Results</h3> There was no difference between sociodemographic factors in groups. Statistically and clinically significant reduction in pain score after one-month treatment (n=20) in patients with negative DN4 score was seen (mean pain relief 26mm vs 17 mm, p&lt;0,05). Significant decrease of WOMAC from baseline to final evaluation in patients without spontaneous NP phenomena (mean WOMAC redaction 315 mm vs 199 mm, p&lt;0,05) was demonstrated. <h3>Conclusions</h3> Patients with clinical signs of CS have suboptimal pain control. Targeting treatment including anticonvulsants or antidepressants to symptoms of CS in people with OA could lead to benefit. <h3>References</h3> Breivik H, Collet B, Ventafridda V, et all, Eur J Pain. 2005; Epub ahead of print. Dieppe PA, Ayis S, Clarke S, Simmons D, Williams S, Fallon 1022 Hochman et al M, et al. Quantitative sensory testing in osteoarthritis of the knee [abstract]. Osteoarthritis Cartilage 2008;16:S204 <h3>Disclosure of Interest</h3> None declared
Tumor Necrosis Factor-Alpha and Interleukin-6 Promoter Gene Polymorphisms in Acquired Bone Marrow Failure Syndromes.
Authors: Vinod K. Gidvani, Shakti H. Ramkissoon, Elaine W. Wong, Lori Mainwaring, Elaine M. Sloand, Neal S. Young
Journal: Blood (2004)
Small-bowel perforation caused by AdvanCE capsule endoscopy delivery device
Authors: Marion Simon, Sandrine Barge, Florence Jeune, Helene Corte, Pierre Cattan, Jean-Marc Gornet
Journal: Endoscopy (2016)

We report herein the case of a 58-year-old-woman who was admitted for hematochezia with acute anemia (hemoglobin 9 g/dL). She had a history of small-bowel adenocarcinoma (T3N0M0) complicating celiac disease; this had been treated by a Whipple procedure 12 years previously, with complete remission since then. She was taking anticoagulants following mitral valve replacement with a mechanical valve, with international normalized ratio (INR) of 2 at the time of admission.
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
Authors: Lisa Pieri, Chiara Paoli, Umberto Arena, Fabio Marra, Fabio Mori, Mery Zucchini, Stefano Colagrande, Alessandro Castellani, Arianna Masciulli, Vittorio Rosti, Valerio De Stefano, Silvia Betti, Guido Finazzi, Maria Luisa Ferrari, Elisa Rumi, Marco Ruggeri, Ilaria Nichele, Paola Guglielmelli, Rajmonda Fjerza, Carmela Mannarelli, Tiziana Fanelli, Lucia Merli, Giuditta Corbizi Fattori, Margherita Massa, Giuseppe Cimino, Alessandro Rambaldi, Giovanni Barosi, Mario Cazzola, Tiziano Barbui, Alessandro M. Vannucchi
Journal: American Journal of Hematology (2016)

Abstract Splanchnic vein thrombosis (SVT) is one of the vascular complications of myeloproliferative neoplasms (MPN). We designed a phase 2 clinical trial to evaluate safety and efficacy of ruxolitinib in reducing splenomegaly and improving disease‐related symptoms in patients with MPN‐associated SVT. Patients diagnosed with myelofibrosis (12 cases), polycythemia vera (5 cases) and essential thrombocythemia (4 cases) received ruxolitinib for 24 weeks in the core study period. Spleen volume was assessed by magnetic resonance imaging (MRI) and splanchnic vein circulation by echo‐Doppler analysis. Nineteen patients carried JAK2 V617F, one had MPL W515L, and one CALR L367fs*46 mutation. Eighteen patients had spleno‐portal‐mesenteric thrombosis, two had Budd–Chiari syndrome, and one had both sites involved; 16 patients had esophageal varices. Ruxolitinib was well tolerated with hematological toxicities consistent with those of patients without SVT and no hemorrhagic adverse events were recorded. After 24 weeks of treatment, spleen volume reduction ≥35% by MRI was achieved by 6/21 (29%) patients, and a ≥50% spleen length reduction by palpation at any time up to week 24 was obtained by 13/21 (62%) patients. At week 72, 8 of the 13 (62%) patients maintained the spleen response by palpation. No significant effect of treatment on esophageal varices or in splanchnic circulation was observed. MPN‐related symptoms, evaluated by MPN‐symptom assessment form (SAF) TSS questionnaire, improved significantly during the first 4 weeks and remained stable up to week 24. In conclusion, this trial shows that ruxolitinib is safe in patients with MPN‐associated SVT, and effective in reducing spleen size and disease‐related symptoms.
Choosing drugs on price alone will stifle innovation, says report
Authors: Nigel Hawkes
Journal: BMJ (2016)

The NHS in England should not focus exclusively on price when buying medicines, says a new report published by the London School of Economics (LSE).1

Doing so risks endangering constructive partnerships between clinicians, NHS managers, and drug companies and conflicts with the government’s aim of balancing affordability with encouraging innovation, the report warned.

While the Pharmaceutical Price Regulation Scheme and HM Treasury both seek to strike this balance, the report warned that growing pressure on NHS budgets will encourage cost saving to the detriment of cooperation and innovation.

Tender Loving Care? was written by Andrew Bonser, a consultant who has worked for Pfizer and Boots; Panos Kanavos, deputy director of LSE Health; and David Taylor, emeritus professor of pharmaceutical and public health policy at University College London. It was commissioned and funded …
IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients
Authors: Susanne Schnittger, Claudia Haferlach, Madlen Ulke, Leyla Kaya, Tamara Weiss, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2009)
Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.
Authors: Hai T. Ngo, Alexey A. Leontovich, Aldo M. Roccaro, Abdel Kareem Azab, Judith M. Runnels, Feda Azab, Antonio Sacco, Phong Quang, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Blood (2009)
CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets
Authors: Sophia Danhof, Tea Gogishvili, Silvia Koch, Martin Schreder, Stefan Knop, Hermann Einsele, Michael Hudecek
Journal: Blood (2015)
PTH-140 Taking Nice Guidelines Further: Straight – To – Test for Dysphagia: Abstract PTH-140 Table 1
Authors: GSZ Tun, M Shiwani, S Anwar, A Masri, A Shirazi-Nejad, N Rezwan, D Bullas, R Atkinson, K Kapur, A Soliman, V Sathyanarayana, E Said
Journal: Gut (2016)

<h3>Introduction</h3> Straight-to-test (STT) endoscopy as a 2 week-wait (2 WW) referral pathway for patients with dysphagia has been operable since 1996 in Barnsley Hospital NHS Foundation Trust. It offers a “one stop assessment” as patients has an “on table” consultation and examination and additional investigations can be requested. It allows direct general practitioner referrals with an aim to reduce delays in cancer management. However, it may reduce endoscopy capacity as patients require a longer time slot (1.5 vs 1.0 slot). We reviewed the clinical outcome of this service. <h3>Methods</h3> Patients were identified through an electronic database "Endosoft" with retrospective analysis of all STT upper gastrointestinal (UGI) endoscopies performed from November 2014-October 2015. Primary end-point was total diagnostic yield with secondary end-point of clinical outcome. <h3>Results</h3> 1192 patients were referred as 2 WW. 398 (33%) of these were STT referrals for dysphagia. 385 proceeded to UGI endoscopy. Ratio of male (M) to female (F) was equal. Mean age in M and F was 63 years (range 26–95 in M and 25–95 in F). Total diagnostic yield is shown in Table 1. Multiple diagnoses co-existed in the same patient. Oesophageal cancer was detected in 6% (18 M, 5 F). Histopathology confirmed adenocarcinoma in 70%, squamous cell carcinoma in 17%, carcinoma in situ in 9% and small cell carcinoma in 4%. All were referred for Multi-Disciplinary Team discussion and had staging Computed Tomography (CT). 4 patients were referred for surgery. 1 patient received radical radiotherapy. 4 received palliative chemo/radiotherapy. The rest were managed with best supportive care. Of the non-cancer patients, 12% (42/362) were discharged from endoscopy. From endoscopy, 9 patients had investigations arranged (2 barium swallows, 4 abdominal ultrasound scans, 3 CT abdomens) and 3 patients were referred to Ears, Nose and Throat. <h3>Conclusion</h3> The STT pathway for dysphagia in our institution helps in maintaining overall prescribed target time for patients for oesophago-gastric cancer. The diagnostic yield for oesophageal cancer was 6%, which is similar to known rates in patients presenting with dysphagia.<sup>1</sup> Other benefits are discharge of patients from endoscopy and expedition of management as investigations and referrals can be made from endoscopy. <h3>Reference</h3> 1 Rosenstock AS, Kushnir VM, Patel A, <i>et al</i>. Su1509 Diagnostic yield in the evaluation of Dysphagia. <i>Gastrointestinal Endoscopy</i>. 2011;<b>73</b>:AB287 <h3>Disclosure of Interest</h3> None Declared
Prognosis of Acute Myeloid Leukemia with Translocation (8;21): A Survey of 142 Cases Investigated in the JALSG AML97 Study.
Authors: Nahoko Hatsumi, Shuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, Fumiharu Yagaski, Kinuko Mitani, Shin Matsuda, Yuji Kishimoto, Yasushi Miyazaki, Norio Asou, Sumihisa Honda, Masafumi Taniwaki, Ryuzo Ohno
Journal: Blood (2005)
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas
Authors: Jill Bayliss, Piali Mukherjee, Chao Lu, Siddhant U. Jain, Chan Chung, Daniel Martinez, Benjamin Sabari, Ashley S. Margol, Pooja Panwalkar, Abhijit Parolia, Melike Pekmezci, Richard C. McEachin, Marcin Cieslik, Benita Tamrazi, Benjamin A. Garcia, Gaspare La Rocca, Mariarita Santi, Peter W. Lewis, Cynthia Hawkins, Ari Melnick, C. David Allis, Craig B. Thompson, Arul M. Chinnaiyan, Alexander R. Judkins, Sriram Venneti
Journal: Science Translational Medicine (2016)

A subset of childhood posterior fossa ependymomas with poor prognosis is epigenetically similar to H3K27M gliomas.
Embracing Complexity in Psychiatric Diagnosis, Treatment, and Research
Authors: Bruce M. Cohen
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Rituximab Does Not Increase the Complication Rate, Particularly Perforation, When Added to Chemotherapy for Patients with Primary B-Cell Lymphomas of the Gastrointestinal Tract.
Authors: Shireen A. Kassam, Anthony H. Goldstone, A. V. Hoffbrand, Miguel Perez-Machado, Nicola Cooper, Panos Kottaridis, Archie Prentice, Derralyn Hughes, Christopher J. McNamara
Journal: Blood (2005)
Evidence is needed to determine if there is a better way to determine the acute:chronic workload
Authors: J A Sampson, H H K Fullagar, A Murray
Journal: British Journal of Sports Medicine (2016)

A series of letters have argued for alternatives to acute:chronic workloads or the methods by which the ratio is calculated when predicting injury risks. Based on the hypothetical data presented by Menaspa,1 Williams et al ,2 argue that an exponentially weighted moving average (EMWA) to emphasise the importance of workloads towards the end of the calculation cycle may be more appropriate. A case is presented in one example (athlete 3) where EWMA calculates a greater injury risk than rolling averages …
Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study
Authors: Aude Charbonnier, Michel Raba, Patrick Ladaique, Laurence Augey, Lilian Laborde, Jeremy Monfray, Carine Champigneulle, Mohamad Sobh, Helene Labussiere-Wallet, Fiorenza Barraco, Sophie Ducastelle, Xavier Thomas, Anne Etienne, Thomas Prebet, Evelyne D'Incan, Jerome Rey, Franck E. Nicolini, Norbert Vey, Mauricette Michallet
Journal: Blood (2014)